Escape hepatitis B virus mutations in recipients of antibody to hepatitis B core antigen-positive liver grafts receiving hepatitis B immunoglobulins

Liver Transplantation

Volumn 16, Issue 7, 2010, Pages 885-894

  Roche, Bruno ^a,b   Roque Afonso, Anne Marie ^a,b   Sebagh, Mylene ^a,b   Delvart, Valerie ^a   Duclos Vallee, Jean Charles ^a,b   Castaing, Denis ^a,b   Samuel, Didier ^a,b  

^a HÔPITAL PAUL BROUSSE   (France)

^b Universite Paris Sud   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ANTIVIRUS AGENT; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIGEN; LAMIVUDINE; NUCLEOTIDE DERIVATIVE; HEPATITIS B HYPERIMMUNE GLOBULIN; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN; NUCLEOSIDE; S ENVELOPE PROTEIN, HEPATITIS B VIRUS; VIRUS ENVELOPE PROTEIN;

ADULT; AGED; ARTICLE; GRAFT INFECTION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; LIVER GRAFT; LONG TERM CARE; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; VIRUS MUTATION; VIRUS TRANSMISSION; ADOLESCENT; GENETICS; IMMUNOLOGY; LIVER TRANSPLANTATION; LONGITUDINAL STUDY; MIDDLE AGED; MUTATION; RETROSPECTIVE STUDY; TRANSPLANTATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HUMANS; IMMUNOGLOBULINS; INCIDENCE; LAMIVUDINE; LIVER TRANSPLANTATION; LONGITUDINAL STUDIES; MIDDLE AGED; MUTATION; NUCLEOSIDES; RETROSPECTIVE STUDIES; RISK FACTORS; TRANSPLANTATION; TREATMENT OUTCOME; VIRAL ENVELOPE PROTEINS; YOUNG ADULT;

EID: 77954153794     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22084     Document Type: Article

References (38)

1. Gallegos-Orozco JF, Vargas HE, Rakela J. Virologically compromised donor grafts in liver transplantation. J Hepatol 2004;41:512-521. (Pubitemid 39297785)
2. Roque-Afonso AM, Feray C, Samuel D, Simoneau D, Roche B, Emile JF, et al. Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBc positive donors. Gut 2002;50:95-99.
3. Prieto M, Gomez MD, Berenguer M, Cordoba J, Rayon JM, Pastor M, et al. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. Liver Transpl 2001;7:51-58.
4. Yu L, Koepsell T, Manhart L, Ioannou G. Survival after orthotopic liver transplantation: the impact of antibody against hepatitis B core antigen in the donor. Liver Transpl 2009;15:1343-1350.
5. Wachs ME, Amend WJ, Ascher NL, Bretan PN, Emond J, Lake JR, et al. The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors. Transplantation 1995;59:230-234.
6. Dickson RC, Everhart JE, Lake JR, Wei Y, Seaberg EC, Wiesner RH, et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology 1997;113:1668-1674.
7. Dodson SF, Issa S, Araya V, Gayowski T, Pinna A, Eghtesad B, et al. Infectivity of hepatic allografts with antibodies to hepatitis B virus. Transplantation 1997;64:1582-1584.
8. Roche B, Samuel D, Gigou M, Feray C, Virot V, Schmets L, et al. De novo and apparent de novo hepatitis B virus infection after liver transplantation. J Hepatol 1997;26:517-526. (Pubitemid 27112716)
9. Yen RD, Bonatti H, Mendez J, Aranda-Michel J, Satyanarayana R, Dickson RC. Case report of lamivudineresistant hepatitis B virus infection post liver transplantation from a hepatitis B core antibody donor. Am J Transplant 2006;6(pt 1):1077-1083. (Pubitemid 44356661)
10. Cholongitas E, Papatheodoridis GV, Burroughs AK. Liver grafts from anti-hepatitis B core positive donors: a systematic review. J Hepatol 2010;52:272-279.
11. Uemoto S, Sugiyama K, Marusawa H, Inomata Y, Asonuma K, Egawa H, et al. Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants. Transplantation 1998;65:494-499.
12. Dodson SF, Bonham CA, Geller DA, Cacciarelli TV, Rakela J, Fung JJ. Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors. Transplantation 1999;68:1058-1061.
13. Nery JR, Nery-Avila C, Reddy KR, Cirocco R, Weppler D, Levi DM, et al. Use of liver grafts from donors positive for antihepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudine. Transplantation 2003;75:1179-1186.
14. Jain A, Orloff M, Abt P, Kashyap R, Mohanka R, Lansing K, et al. Use of hepatitis B core antibody-positive liver allograft in hepatitis C virus-positive and -negative recipients with use of short course of hepatitis B immunoglobulin and lamivudine. Transplant Proc 2005;37:3187-3189.
15. Chang SH, Suh KS, Yi NJ, Choi SH, Lee HJ, Seo JK, et al. Active immunization against de novo hepatitis B virus infection in pediatric patients after liver transplantation. Hepatology 2003;37:1329-1334.
16. Holt D, Thomas R, Van Thiel D, Brems JJ. Use of hepatitis B core antibody-positive donors in orthotopic liver transplantation. Arch Surg 2002;137:572-575.
17. Loss GE Jr, Mason AL, Nair S, Blazek J, Farr G, Guo L, et al. Does lamivudine prophylaxis eradicate persistent HBV DNA from allografts derived from anti-HBc-positive donors? Liver Transpl 2003;9:1258-1264.
18. Chen YS, Wang CC, de Villa VH, Wang SH, Cheng YF, Huang TL, et al. Prevention of de novo hepatitis B virus infection in living donor liver transplantation using hepatitis B core antibody positive donors. Clin Transplant 2002;16:405-409.
19. Yu AS, Vierling JM, Colquhoun SD, Arnaout WS, Chan CK, Khanafshar E, et al. Transmission of hepatitis B infection from hepatitis B core antibody-positive liver allografts is prevented by lamivudine therapy. Liver Transpl 2001;7:513-517.
20. Prakoso E, Strasser SI, Koorey DJ, Verran D, McCaughan GW. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors. Clin Transplant 2006;20:369-373.
21. Perrillo R. Hepatitis B virus prevention strategies for antibody to hepatitis B core antigen-positive liver donation: a survey of North American, European, and Asian-Pacific transplant programs. Liver Transpl 2009;15:223-232.
22. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993;329:1842-1847.
23. Moraleda G, Barcena R, Del Campo S, Oton E, Moreno J, Foruni JR. De novo HBV infection caused by an anti-HBc positive donor in a vaccinated liver transplant recipient in spite of anti-HBs response. Am J Transplant 2006;6:438-440.
24. Yoshida EM, Ramji A, Erb SR, Davis JE, Steinbrecher UP, Sherlock CH, et al. De novo acute hepatitis B infection in a previously vaccinated liver transplant recipient due to a strain of HBV with a Met 133 Thr mutation in the "a" determinant. Liver 2000;20:411-414.
25. Barcena R, Moraleda G, Moreno J, Martin MD, de Vicente E, Nuno J, et al. Prevention of de novo HBV infection by the presence of anti-HBs in transplanted patients receiving core antibody-positive livers. World J Gastroenterol 2006;12:2070-2074.
26. Dumortier J, Chevallier P, Scoazec JY, Boillot O. HBV reactivation in the recipient of a liver graft from an anti-HBc positive donor despite post-vaccination antibodies to hepatitis B surface antigen. J Hepatol 2002;37:876-877.
27. Umeda M, Marusawa H, Ueda M, Takada Y, Egawa H, Uemoto S, et al. Beneficial effects of short-term lamivudine treatment for de novo hepatitis B virus reactivation after liver transplantation. Am J Transplant 2006;6:2680-2685.
28. Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004;126:1750-1758.
29. Hochberger S, Althof D, Gallegos de Schrott R, Nachbaur N, Rock H, Leying H. Fully automated quantitation of hepatitis B virus (HBV) DNA in human plasma by the COBAS AmpliPrep/COBAS TaqMan system. J Clin Virol 2006;35:373-380.
30. French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994;20(pt 1):15-20.
31. Faria LC, Gigou M, Roque-Afonso AM, Sebagh M, Roche B, Fallot G, et al. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Gastroenterology 2008;134:1890-1899. (Pubitemid 351783254)
32. Schilling R, Ijaz S, Davidoff M, Lee JY, Locarnini S, Williams R, et al. Endocytosis of hepatitis B immune globulin into hepatocytes inhibits the secretion of hepatitis B virus surface antigen and virions. J Virol 2003;77:8882-8892.
33. Roche B, Feray C, Gigou M, Roque-Afonso AM, Arulnaden JL, Delvart V, et al. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis. Hepatology 2003;38:86-95.
34. Su WJ, Ho MC, Ni YH, Chen HL, Hu RH, Wu YM, et al. High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection. J Pediatr Gastroenterol Nutr 2009;48:203-208.
35. Horlander JC, Boyle N, Manam R, Schenk M, Herring S, Kwo PY, et al. Vaccination against hepatitis B in patients with chronic liver disease awaiting liver transplantation. Am J Med Sci 1999;318:304-307. (Pubitemid 30349663)
36. Lee KW, Lee DS, Lee HH, Kim SJ, Joh JW, Seo JM, et al. Prevention of de novo hepatitis B infection from HbcAbpositive donors in living donor liver transplantation. Transplant Proc 2004;36:2311-2312.
37. Gunther M, Neuhaus R, Bauer T, Jilg W, Holtz JA, Bienzle U. Immunization with an adjuvant hepatitis B vaccine in liver transplant recipients: antibody decline and booster vaccination with conventional vaccine. Liver Transpl 2006;12:316-319.
38. Fabrega E, Garcia-Suarez C, Guerra A, Orive A, Casafont F, Crespo J, et al. Liver transplantation with allografts from hepatitis B core antibody-positive donors: a new approach. Liver Transpl 2003;9:916-920.